Cargando…

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours

BACKGROUND: Bromodomain and extra-terminal domain (BET) proteins are reported to be epigenetic anti-cancer drug targets. This first-in-human study evaluated the safety, pharmacokinetics and preliminary anti-tumour activity of the BET inhibitor ODM-207 in patients with selected solid tumours. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ameratunga, Malaka, Braña, Irene, Bono, Petri, Postel-Vinay, Sophie, Plummer, Ruth, Aspegren, John, Korjamo, Timo, Snapir, Amir, de Bono, Johann S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722752/ https://www.ncbi.nlm.nih.gov/pubmed/32989226 http://dx.doi.org/10.1038/s41416-020-01077-z

Ejemplares similares

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours
por: Bono, Petri, et al.
Publicado: (2020)

ODM2CDA and CDA2ODM: Tools to convert documentation forms between EDC and EHR systems
por: Dugas, Martin
Publicado: (2015)

How Much Can We Bet on Activity of BET Inhibitors Beyond NUT–Midline Carcinoma?
por: Martin-Romano, Patricia, et al.
Publicado: (2019)

An IMU/ODM/UWB Joint Localization System Based on Modified Cubature Kalman Filtering
por: Tang, Chao, et al.
Publicado: (2021)

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer
por: Fizazi, Karim, et al.
Publicado: (2015)

Levels in $^{207}$Po populated in the decay of $^{207}$At
por: Jonson, B, et al.
Publicado: (1970)

Levels in $^{207}Po$ populated in the decay of $^{207}At$
por: Jonson, B, et al.
Publicado: (1971)

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
por: Molife, L R, et al.
Publicado: (2010)

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients
por: Lallous, Nada, et al.
Publicado: (2021)

The decay $^{207}_{80}$Hg --> $^{207}_{81}$Tl
por: Jonson, B, et al.
Publicado: (1981)

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials
por: Ingles Garces, Alvaro H., et al.
Publicado: (2018)

At R207
Publicado: (1975)

At R207
Publicado: (1975)

ODM Data Analysis—A tool for the automatic validation, monitoring and generation of generic descriptive statistics of patient data
por: Brix, Tobias Johannes, et al.
Publicado: (2018)

Gamma-ray transition in $^{207}$Bi following the decay of $^{207}$Po
por: Alpsten, M, et al.
Publicado: (1970)

Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach
por: Coleman, Niamh, et al.
Publicado: (2018)

Comparison and transformation between CDISC ODM and EN13606 EHR standards in connecting EHR data with clinical trial research data
por: Tapuria, Archana, et al.
Publicado: (2018)

Expression of TMEM207 in Colorectal Cancer: Relation between TMEM207 and Intelectin-1
por: Maeda, Kenichi, et al.
Publicado: (2016)

TMEM207 hinders the tumour suppressor function of WWOX in oral squamous cell carcinoma
por: Bunai, Katsuaki, et al.
Publicado: (2017)

Targeting BET bromodomain proteins in solid tumors
por: Sahai, Vaibhav, et al.
Publicado: (2016)

Memorandum 207: plans for 1985
por: Garreta, D
Publicado: (1984)

Another view of R207
Publicado: (1975)

Health Tract, No. 207: Inheritances
Publicado: (1864)

Health Tract, No. 207: Inheritances
Publicado: (1865)

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas
por: Moreno, Victor, et al.
Publicado: (2023)

Dramatic clinical response in the treatment of small cell glioblastoma multiforme
por: Zaman, Farzana Yasmin, et al.
Publicado: (2022)

Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
por: Moilanen, Anu-Maarit, et al.
Publicado: (2015)

Phase I trial outcomes in older patients with advanced solid tumours
por: Khan, K H, et al.
Publicado: (2016)

Nuclear magnetic moment of $^{207}$Tl
por: Neugart, R, et al.
Publicado: (1985)

Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017)

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
por: Postel-Vinay, S, et al.
Publicado: (2009)

To Bet or Not to Bet on T-bet As a Therapeutic Target in Emphysema?
por: Wang, Xiaoyun, et al.
Publicado: (2019)

CNS cancer immunity cycle and strategies to target this for glioblastoma
por: Ameratunga, Malaka, et al.
Publicado: (2018)

PS console GPIB transceiver no. 80 207
por: Debordes, R
Publicado: (1979)

R207 at intersection I2, ISR
por: CERN PhotoLab
Publicado: (1976)

R207 at intersection I2, ISR
Publicado: (1975)

R207 at intersection I2, ISR
Publicado: (1975)

R207 at intersection I2, ISR
Publicado: (1975)

Resonance capture cross section of 207Pb
por: Domingo-Pardo, C., et al.
Publicado: (2006)

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
por: Papadatos-Pastos, Dionysis, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dj7msgskb9lpkm86550au6b5u3